Your browser doesn't support javascript.
loading
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli, Paola; Barosi, Giovanni; Rambaldi, Alessandro; Marchioli, Roberto; Masciulli, Arianna; Tozzi, Lorenzo; Biamonte, Flavia; Bartalucci, Niccolò; Gattoni, Elisabetta; Lupo, Maria Letizia; Finazzi, Guido; Pancrazzi, Alessandro; Antonioli, Elisabetta; Susini, Maria Chiara; Pieri, Lisa; Malevolti, Elisa; Usala, Emilio; Occhini, Ubaldo; Grossi, Alberto; Caglio, Silvia; Paratore, Simona; Bosi, Alberto; Barbui, Tiziano; Vannucchi, Alessandro M.
Affiliation
  • Guglielmelli P; Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy.
Blood ; 118(8): 2069-76, 2011 Aug 25.
Article in En | MEDLINE | ID: mdl-21725052
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Sirolimus / Protein Kinase Inhibitors / Primary Myelofibrosis / TOR Serine-Threonine Kinases Type of study: Clinical_trials / Etiology_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2011 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Sirolimus / Protein Kinase Inhibitors / Primary Myelofibrosis / TOR Serine-Threonine Kinases Type of study: Clinical_trials / Etiology_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2011 Type: Article